LEADER 05912nam 2200577 a 450 001 9910957634103321 005 20251116181920.0 010 $a1-62257-499-0 035 $a(CKB)2550000001043640 035 $a(EBL)3021730 035 $a(SSID)ssj0001179332 035 $a(PQKBManifestationID)11721202 035 $a(PQKBTitleCode)TC0001179332 035 $a(PQKBWorkID)11169984 035 $a(PQKB)11147952 035 $a(MiAaPQ)EBC3021730 035 $a(Au-PeEL)EBL3021730 035 $a(CaPaEBR)ebr10683470 035 $a(OCoLC)846979612 035 $a(BIP)40228448 035 $a(EXLCZ)992550000001043640 100 $a20120620d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSeptic shock $esymptoms, management and risk factors /$fMelvin C. Johnston and Jerome E. Knight, editors 205 $a1st ed. 210 $aNew York $cNova Science Publishers, Inc.$d2012 215 $a1 online resource (177 p.) 225 0 $aEmergency and intensive care medicine 300 $a"Nova biomedical." 311 08$a1-62257-485-0 320 $aIncludes bibliographical references and index. 327 $aIntro -- SEPTIC SHOCK: SYMPTOMS, MANAGEMENT AND RISK FACTORS -- SEPTIC SHOCK: SYMPTOMS, MANAGEMENT AND RISK FACTORS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter 1: Pathophysiology of Cardiovascular Failure in Septic Shock -- Abstract -- Introduction -- 1. Molecular Mechanisms in the Pathophysiology of Septic Shock -- 1.1. Changes of Myocyte ion Transport by Inflammatory Mediators -- Calcium Channels -- Potassium Channels -- 1.3. Changes in Cytoskeletal Proteins -- 1.3. Mitochondrial Dysfunction in Septic Shock -- 1.4. The Role of Endotoxins and Bacterial Virulence Factors in Septic Shock -- Endotoxin -- Effects of other Bacterial Toxins -- 2. Microcirculation in Septic Shock -- 3. Myocardial Dysfunction in Septic Shock -- 3.1. The role of Cytokines in Myocardial Dysfunction -- 3.2. Myocardial Cell Death -- 3.2.1. The Role of Poly(Adenosine 5'-diphosphate-ribose) -- Polymerase Activation -- 3.2.2. The Role of Nitric Oxide -- 4. Pathophysiology of Inotrope Refractory Cardiovascular Failure -- Conclusion -- References -- Chapter 2: Sepsis and Septic Shock: Risk Factors, Symptoms and Management -- Abstract -- Introduction -- Risk Factors -- Definitions -- Pathogenesis -- Symptoms -- Management -- Early Management -- Ongoing Management -- Recommendations -- References -- Chapter 3: Septic Shock: Clinical Diagnosis and Risk Factors -- Abstract -- Abbreviations -- 1. Introduction -- 1.1. Basic Concepts -- 1.2. Epidemiological Impact of Sepsis and Septic Shock -- 2. Clinical Approach to the Septic Patient -- 2.1. Suspected Sepsis in the ER -- 2.2. Patients at Risk of Septic Shock -- 2.3. Confirming the Diagnosis -- 2.3.1. Laboratory Analyses and Work-Up -- 2.3.2. Imaging Studies -- 2.3.3. New Diagnostic Tools and Future Research -- 2.3.3.1. Inflammatory Biomarkers -- 2.3.3.2. Oxidative Stress Biomarkers. 327 $aConclusion -- References -- Chapter 4: Diagnosis and Management of Life-Threatening Infections and Septic Shock During Idiopathic Drug-Induced Agranulocytosis -- Abstract -- Introduction -- Criteria for the Definition of Idiopathic Drug-Induced Agranulocytosis -- Epidemiology of Agranulocytosis -- Incriminated Drugs in Idiopathic Agranulocytosis -- Clinical Manifestations of Drug-Induced Neutropenia and Agranulocytosis -- Differential Diagnosis of Acute Neutropenia -- Prognosis and Mortality Rate of Drug Induced Agranulocytosis, Frailty Patients -- Management of Drug-Induced Severe Neutropenia or Agranulocytosis -- Prevention -- General Measures -- Indications of Antimicrobial Agents -- Indications of Hematopoietic Growth Factors -- Conclusion -- References -- Chapter 5: Sepsis: A Disease of the Microcirculation -- Abstract -- Introduction -- Microcirculation -- The Shunting Theory of Sepsis -- Monitoring the Microcirculation -- Nailfold videocapillaroscopy -- Laser Doppler -- Orthogonal Polarization Spectral -- and Sidestream Dark Field Imaging -- Near-Infrared Spectroscopy -- The Microcirculation in Sepsis -- Sepsis and Outcome -- Vasopressors and Inotropes -- Norepinephrine -- Dobutamine -- Levosimendan -- Vasodilators -- Red Blood Cell Transfusion -- Fluids -- Steroids -- Sedatives -- Conclusion -- References -- Chapter 6: The Role of HMGB1 in Cardiac Dysfunction During Septic Shock -- Abstract -- Introduction -- Mechanism of Sepsis-Related -- Cardiac Dysfunction -- The Role of HMGB1 in Sepsis -- and as a Potential Therapeutic Target -- Conclusion -- References -- Chapter 7: Pathophysiology of Sepsis and Septic Shock -- Abstract -- Abbreviations -- 2. Introduction -- 3. Pathophysiology of Sepsis -- 3.1. Basic Molecular Mechanisms of Inflammation in Sepsis -- 3.1.1. Pathogen-Host Interaction -- 3.1.2. Neutrophils -- 3.1.3. Cytokines. 327 $a3.1.4. Coagulation Disorders in Sepsis -- 3.1.5. Endothelial Cells -- 3.1.6. Complement Activation -- 3.2. Immunoparalysis -- 4. Pathophysiology of Septic Shock -- Conclusion and Future Goals -- References -- Index. 330 $aSeptic shock is a common and lethal condition that remains one of the leading causes of death in the hospital. Greater awareness, understanding of the condition and knowledge of effective management may decrease the mortality rate. In this book, the authors discuss the symptoms, management and risk factors of septic shock. 410 0$aEmergency and Intensive Care Medicine 606 $aSeptic shock 615 0$aSeptic shock. 701 $aJohnston$b Melvin C$01866643 701 $aKnight$b Jerome E$01866644 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910957634103321 996 $aSeptic shock$94474057 997 $aUNINA